Related Experiment Video
Updated: Nov 8, 2025
10:05
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.5K
Endogenous Cardiotonics: Search and Problems
Arkady R Kolpakov1, Roman A Knyazev1
1Institute of Biochemistry of Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russian Federation.
Cardiovascular & Hematological Disorders Drug Targets
|April 20, 2021
Summary
This review explores endogenous compounds for treating chronic cardiac failure, highlighting apoprotein A-1
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Current chronic cardiac failure treatments focus on reducing heart load.
- cAMP-dependent cardiotonic drugs are unsuitable for long-term use due to increased oxygen demand.
- Digoxin has been the primary drug for enhancing myocardial performance.
Purpose of the Study:
- To review current data on endogenous compounds affecting heart performance.
- To discuss challenges in translating scientific findings into clinical practice.
- To present research on the cardiotropic properties of serum lipoproteins.
Main Methods:
- Literature review of endogenous compounds (NO, CO, steroids, fatty acids, polypeptides, proteins).
- Analysis of studies on cardiotropic properties of serum lipoproteins.
- Experimental investigation of apoprotein A-1's effect on heart performance.
Main Results:
- Endogenous compounds like NO, CO, steroids, and others influence heart performance.
- Serum lipoproteins exhibit cardiotropic activity.
- Apoprotein A-1 demonstrates cardiotonic activity with reduced oxygen consumption.
Conclusions:
- Apoprotein A-1 shows promise as a cardiotonic agent with improved oxygen efficiency.
- Further research is needed to overcome challenges in clinical application of new findings.
- Endogenous compounds offer potential alternatives for managing chronic cardiac failure.
Keywords:
Cardiac failureapoprotein A-1.digoxinendogenous cardiotonic compoundsinotropic preparationsserum lipoproteinsMore Related Videos
09:20Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
Published on: July 5, 2021
3.3K
06:40Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
Published on: May 22, 2018
10.9K
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
912
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
912
01:30Cardiomyopathy II: Dilated Cardiomyopathy
121
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
121
01:25Dysrhythmias VI: Management of Dysrhythmias
194
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
194
01:29Cardiomyopathy V: Interprofessional Care
104
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
104
01:30Dysrhythmias V: Evaluating Dysrhythmias
175
Dysrhythmias, also known as arrhythmias, are disturbances in the heart's rhythm that range from benign to life-threatening. A thorough evaluation is crucial for appropriate management and involves a comprehensive medical history, physical examination, and various diagnostic tests.Medical HistorySymptoms: Collect detailed information on palpitations, dizziness, syncope, chest pain, and fatigue. Note their onset, frequency, and triggers.Previous Cardiac Issues: Document any history of heart...
175
01:22Heart Failure VI: Adjunct Therapies
75
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
75